<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28668682</PMID><DateCompleted><Year>2018</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7913</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Jan</Month></PubDate></JournalIssue><Title>International journal of antimicrobial agents</Title><ISOAbbreviation>Int J Antimicrob Agents</ISOAbbreviation></Journal><ArticleTitle>Inhibition of herpes simplex virus 1 (HSV-1) and poliovirus (PV-1) by bacteriocins from lactococcus lactis subsp. lactis and enterococcus durans strains isolated from goat milk.</ArticleTitle><Pagination><StartPage>33</StartPage><EndPage>37</EndPage><MedlinePgn>33-37</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijantimicag.2017.04.020</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0924-8579(17)30229-7</ELocationID><Abstract><AbstractText>Bacteriocins have unusual inhibitory activity, including antiviral properties, and this can be exploited to give alternative applications. Semi-purified bacteriocins of six lactic acid bacteria (LAB) strains isolated from goat milk (two Lactococcus lactis: GLc03 and GLc05, and four Enterococcus durans: GEn09, GEn12, GEn14 and GEn17) were tested for cytotoxicity in Vero cells (50% Cytotoxicity Concentration: CC<sub>50</sub>), and for their antiviral activities against herpes simplex virus 1 (HVS-1) and poliovirus (PV-1). Semi-purified bacteriocins presented low cytotoxicity, with CC<sub>50</sub> varying from 256.2&#x2009;&#xb5;g/mL (GLc05) to 1084.5&#x2009;&#xb5;g/mL (GEn14). CC<sub>10</sub> was determined for all isolates (GLc03: 36.9&#x2009;&#xb5;g/mL; GLc05: 51.2&#x2009;&#xb5;g/mL; GEn09: 88.1&#x2009;&#xb5;g/mL; GEn12: 99.9&#x2009;&#xb5;g/mL; GEn14: 275&#x2009;&#xb5;g/mL; and GEn17: 62.2&#x2009;&#xb5;g/mL) and considered for antiviral activity assays. Antiviral activity before virus adsorption was recorded against PV-1 for GLc05 (4.9%), GEn09 (3.4%), GEn12 (24.7%) and GEn17 (23.5%), and against HSV-1 for GEn12 (27.9%), GEn14 (58.7%) and GEn17 (39.2%). Antiviral activity after virus adsorption was identified against PV-1 for GLc05 (32.7%), GEn09 (91.0%), GEn12 (93.7%) and GEn17 (57.2%), and against HSV-1 for GEn17 (71.6%). The results obtained indicate the potential of some bacteriocins, particularly those produced by E. durans strains investigated in the present study, in viral inhibition and their application as new antiviral agents.</AbstractText><CopyrightInformation>Copyright &#xa9; 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cavicchioli</LastName><ForeName>Val&#xe9;ria Quintana</ForeName><Initials>VQ</Initials><AffiliationInfo><Affiliation>Universidade Federal de Vi&#xe7;osa, Departamento de Veterin&#xe1;ria, Campus UFV, 36570-900, Vi&#xe7;osa, MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carvalho</LastName><ForeName>Ot&#xe1;vio Val&#xe9;rio de</ForeName><Initials>OV</Initials><AffiliationInfo><Affiliation>Universidade Federal de Vi&#xe7;osa, Departamento de Veterin&#xe1;ria, Campus UFV, 36570-900, Vi&#xe7;osa, MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paiva</LastName><ForeName>Janine Cerqueira de</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Universidade Federal de Vi&#xe7;osa, Departamento de Bioqu&#xed;mica e Biologia Molecular, Campus UFV, 36570-900, Vi&#xe7;osa, MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Todorov</LastName><ForeName>Svetoslav Dimitrov</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Universidade Federal de Vi&#xe7;osa, Departamento de Veterin&#xe1;ria, Campus UFV, 36570-900, Vi&#xe7;osa, MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silva J&#xfa;nior</LastName><ForeName>Abelardo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Universidade Federal de Vi&#xe7;osa, Departamento de Veterin&#xe1;ria, Campus UFV, 36570-900, Vi&#xe7;osa, MG, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nero</LastName><ForeName>Lu&#xed;s Augusto</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Universidade Federal de Vi&#xe7;osa, Departamento de Veterin&#xe1;ria, Campus UFV, 36570-900, Vi&#xe7;osa, MG, Brazil. Electronic address: nero@ufv.br.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>06</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Antimicrob Agents</MedlineTA><NlmUniqueID>9111860</NlmUniqueID><ISSNLinking>0924-8579</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001430">Bacteriocins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001430" MajorTopicYN="N">Bacteriocins</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016983" MajorTopicYN="N">Enterococcus</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006041" MajorTopicYN="N">Goats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018259" MajorTopicYN="N">Herpesvirus 1, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013294" MajorTopicYN="N">Lactococcus lactis</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008892" MajorTopicYN="N">Milk</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antiviral activity</Keyword><Keyword MajorTopicYN="N">Bacteriocins</Keyword><Keyword MajorTopicYN="N">Herpes virus</Keyword><Keyword MajorTopicYN="N">Lactic acid bacteria</Keyword><Keyword MajorTopicYN="N">Poliovirus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>4</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28668682</ArticleId><ArticleId IdType="doi">10.1016/j.ijantimicag.2017.04.020</ArticleId><ArticleId IdType="pii">S0924-8579(17)30229-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>